Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Teradyne, Inc. — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Teradyne, Inc. trades at $352.33 (market cap $59.45B). The key difference: Teradyne, Inc. is far larger — about 7.9× Spyre Therapeutics Inc. Common Stock's market cap, and Teradyne, Inc. pays a 0.14% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Teradyne, Inc. for 37 Days on average.
| SYRE | TER | |
|---|---|---|
Market Cap | $7.52B | $59.45B |
Volume | 1,441,031 | 2,735,541 |
Sector | Health | Technology |
52-Week High | $108.92 | $483.84 |
52-Week Low | $22.18 | $138.09 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $6.52B | $59.20B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Teradyne (TER) trades at $359.44, down 6.36% over 24 hours, reflecting recent bearish technical signals. The stock shows strong fundamentals with a 25.77% net income margin and consistent earnings beats in recent quarters. Recent news highlights expansion in AI-driven test equipment, including the Magnum E2 and Iris 100 platforms, targeting growth in semiconductor and data center markets. Analyst consensus remains bullish with a $461.50 price target, though technical indicators suggest near-term caution.
Outlook is positive due to robust profitability and AI-related demand, but risks include competitive pressures and market volatility. The stock offers growth potential if execution aligns with analyst expectations, though investors should monitor earnings consistency and industry trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
